344 related articles for article (PubMed ID: 26100396)
1. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
Serratrice C; Swiader L; Serratrice J
J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
[TBL] [Abstract][Full Text] [Related]
2. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
[TBL] [Abstract][Full Text] [Related]
3. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
4. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
[No Abstract] [Full Text] [Related]
5. Enzyme replacement and substrate reduction therapy for Gaucher disease.
Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
[TBL] [Abstract][Full Text] [Related]
6. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
8. Neurologic improvement in a type 3 Gaucher disease patient treated with imiglucerase/miglustat combination.
Capablo JL; Franco R; de Cabezón AS; Alfonso P; Pocovi M; Giraldo P
Epilepsia; 2007 Jul; 48(7):1406-8. PubMed ID: 17433057
[TBL] [Abstract][Full Text] [Related]
9. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
[TBL] [Abstract][Full Text] [Related]
10. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
Weinreb NJ; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P
Am J Hematol; 2005 Nov; 80(3):223-9. PubMed ID: 16247743
[TBL] [Abstract][Full Text] [Related]
11. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
[TBL] [Abstract][Full Text] [Related]
12. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
[TBL] [Abstract][Full Text] [Related]
13. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
Moyses C
Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
[TBL] [Abstract][Full Text] [Related]
14. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Pastores GM; Barnett NL; Kolodny EH
Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
[TBL] [Abstract][Full Text] [Related]
15. Substrate reduction therapy of glycosphingolipid storage disorders.
Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
[TBL] [Abstract][Full Text] [Related]
16. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
[TBL] [Abstract][Full Text] [Related]
17. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
18. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
[TBL] [Abstract][Full Text] [Related]
19. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]